May 31 |
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
|
May 31 |
Ionis hereditary angioedema therapy succeeds in late-stage trials
|
May 31 |
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
|
May 28 |
Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
|
May 28 |
Ionis to hold donidalorsen Phase 3 data webcast
|
May 24 |
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
|
May 23 |
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUAâ„¢ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
|
May 17 |
Ionis, Biogen Down on Ending Development of ALS Drug
|
May 17 |
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
|
May 16 |
Biogen also drops collaboration with Ionis on Angelman syndrome candidate
|